↑ 薬物リストへ　← 戻る

Dexamethasone sodium phosphate    (DrugBank: Dexamethasone, Phosphate)

3 diseases
告示番号疾患名（ページ内リンク）臨床試験数
65原発性免疫不全症候群9
70広範脊柱管狭窄症1
96クローン病2

65. 原発性免疫不全症候群　［臨床試験数：413，薬物数：581（DrugBank：97），標的遺伝子数：68，標的パスウェイ数：202］
Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "Telangiectasia ataxia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "IMyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "CC1r deficiency", "CC1s deficiency", "CC2 deficiency", "CC3 deficiency", "CC4 deficiency", "CC5 deficiency", "CC6 deficiency", "CC7 deficiency", "CC8 deficiency", "CC9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 413 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-000338-36-NO
(EUCTR)		06/11/202004/02/2020Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		155Phase 3United States;Spain;Poland;Belgium;Australia;Tunisia;Germany;Norway;United Kingdom;Italy;India
2EUCTR2018-000338-36-GB
(EUCTR)		27/05/202020/01/2020Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT, version 5.0 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		51Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Norway;Germany;United Kingdom;India
3EUCTR2018-000338-36-DE
(EUCTR)		20/09/201821/06/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		155Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Norway;Germany;United Kingdom;India
4EUCTR2018-000338-36-ES
(EUCTR)		31/05/201805/04/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 20.1;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		61Phase 3United States;Poland;Belgium;Spain;Australia;Israel;Norway;Germany;Italy;United Kingdom;India
5EUCTR2015-005241-31-IT
(EUCTR)		02/11/201628/02/2018n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 20.1;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexametasone Fosfato Sodico
INN or Proposed INN: Dexametasone Fosfato Sodico
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		ERYDEL S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		180Phase 3United States;Spain;Costa Rica;Turkey;Israel;Italy;United Kingdom;Belgium;Poland;Australia;Tunisia;Germany;Norway
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2015-005241-31-DE
(EUCTR)		14/09/201627/05/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - Ataxia Telangiectasia - Treatment with EryDex SysTem - ATTEST Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		175Phase 3United States;Spain;Poland;Belgium;Australia;Israel;Tunisia;Norway;Germany;United Kingdom;Italy;India
7EUCTR2015-005241-31-ES
(EUCTR)		31/05/201609/06/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 19.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLNot RecruitingFemale: yes
Male: yes		180Phase 3United States;Spain;Costa Rica;Turkey;Israel;United Kingdom;Italy;Belgium;Poland;Australia;Tunisia;Germany;Norway
8EUCTR2018-000338-36-PL
(EUCTR)		06/11/2018Not ApplicableOpen-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - OLE-IEDAT Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLNAFemale: yes
Male: yes		155Phase 3United States;Spain;Belgium;Poland;Australia;Tunisia;Norway;Germany;United Kingdom;Italy;India
9EUCTR2015-005241-31-PL
(EUCTR)		01/07/2016n/aA Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia - EDS in Ataxia Telangiectasia Patients - IEDAT-02 Patient with neurological symptoms of Ataxia Telangiectasia
MedDRA version: 21.0;Level: PT;Classification code 10003594;Term: Ataxia telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Dexamethasone sodium phosphate
INN or Proposed INN: Dexamethasone sodium phosphate
Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.		EryDel S.p.A.NULLNAFemale: yes
Male: yes		180Phase 3United States;Spain;Costa Rica;Turkey;Israel;United Kingdom;Italy;India;Poland;Belgium;Australia;Norway;Tunisia;Germany

先頭へ


70. 広範脊柱管狭窄症　［臨床試験数：91，薬物数：195（DrugBank：54），標的遺伝子数：60，標的パスウェイ数：85］
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 91 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04537026
(ClinicalTrials.gov)		January 15, 202128/8/2020The SAFE Trial. Sterile Amniotic Fluid Filtrate Epidural Injection.A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the Treatment of Lumbosacral Radicular Pain Due to Spinal Stenosis: The SAFE Trial (Improving Safety and Outcomes in the Treatment of Pain and Disability Related to Spinal Stenosis).Lumbar Spinal StenosisDrug: Amniotic Fluid Allograft;Drug: Dexamethasone sodium phosphateUniversity of UtahCell Therapy & Regenerative Medicine;SKAGGs FoundationNot yet recruiting18 YearsN/AAll112Phase 1;Phase 2NULL

96. クローン病　［臨床試験数：2,209，薬物数：1,276（DrugBank：240），標的遺伝子数：166，標的パスウェイ数：210］
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2008-007329-38-ES
(EUCTR)		24/07/200924/04/2009Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexametasona intraeritrocitaria comparada con un placebo en pacientes con enfermedad de Crohn dependiente de esteroides - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s DiseaseEstudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexametasona intraeritrocitaria comparada con un placebo en pacientes con enfermedad de Crohn dependiente de esteroides - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease Pacientes con enfermedad de Crohn dependiente de esteroides
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease		Product Name: dexamethasone sodium phosphate 250 mg/ 10 ml
Product Code: ERY-DEX
INN or Proposed INN: fosfato sodico de dexametasona		ERYDEL S.P.A.NULLNot RecruitingFemale: yes
Male: yes		184Spain;Italy
2EUCTR2008-007329-38-IT
(EUCTR)		06/02/200921/01/2009Multicenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn?s disease - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s DiseaseMulticenter, randomized, double-blind, parallel-group study of intra-erythrocyte dexamethasone versus placebo in patients with steroid-dependent Crohn?s disease - Intra-erythrocyte dexamethasone in patients with steroid-dependent Crohn?s Disease Patients with steroid-dependent Crohn?s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease		Product Name: dexamethasone sodium phosphate 250 mg/ 10 ml
Product Code: ERY-DEX
INN or Proposed INN: dexamethasone sodium phosphate		ERYDEL S.P.A.NULLNot RecruitingFemale: yes
Male: yes		184Spain;Italy

先頭へ